The intersection of protein disulfide isomerase and cancer associated thrombosis.
Thromb Res, 2018/04;164 Suppl 1:S130-S135.
Stopa JD[1], Zwicker JI[2]
Affiliations
PMID: 29703471DOI: 10.1016/j.thromres.2018.01.005
Impact factor: 10.407
Abstract
The mechanisms underlying the hypercoagulability of cancer are complex and include the upregulation coagulation factors or procoagulant proteins, shedding of microparticles, and direct activation of vascular cells. Protein disulfide isomerase (PDI) is a thiol isomerase secreted from activated platelets and endothelial cells and plays a critical role in both platelet aggregation and fibrin generation. A number of potential intravascular targets of PDI have been identified including cell surface receptors (e.g. β-integrins and glycoprotein Ib), receptor ligands (e.g. fibrinogen and von Willebrand factor), serine proteases (e.g. cathepsin G and kallekrein-14), and coagulation factors (e.g. factor XI and factor V). Recent clinical studies demonstrated that a small molecule inhibitor of PDI, isoquercetin, decreases platelet-dependent thrombin generation and PDI activity in plasma following oral administration. This review explores the mechanistic overlap between the molecular drivers of cancer associated thrombosis and the potential roles PDI plays in mediating thrombosis. These molecular insights provide rationale for clinical trials targeting PDI to prevent thrombosis in cancer patients.
Keywords: Antithrombotics; Cancer associated thrombosis; Protein disulfide isomerase
MeSH terms
More resources
Full text:
Europe PubMed Central; PubMed Central
EndNote: Download